INTRODUCTION
Parkinson's disease (PD) is a neurodegenerative disease characterized by motor manifestation, autonomic disorder, sensorial symptoms and neurological disorder that compromises the patient's quality of life (QoL) [1, 2] .
Due to the progressive nature of the disease, the patient's QoL is compromised in physical, mental/emotional, social and economic aspects.
The most common and relevant factors reviewed in the literature about the worsening of PD patients' QoL were bradykinesia, tremor, rigidity, postural instability, gait disorder, pain, fatigue, depression, and sexual and cognitive disorders [3, 4] . A Brazilian study showed that the major QoL determinants include mood disorder (mainly depression), disability, PD complications (dyskinesia and fluctuation) and educational attainment [2] .
Therapy for PD is effective in the treatment of motor symptoms, but it does not prevent the disease's progression. The worsening of motor symptoms associated with the occurrence of non-motor symptoms evolves progressively.
This situation leads to dosage increase and need of new medication. Some antiparkinsonians, mainly levodopa, develop motor complications (fluctuation and dyskinesia) in the long term, making the treatment complex, increasing the demands for care and more expensive and invasive procedures [5, 6] . As a result of the treatment, PD patients can experience medicine-related problems, which are also called DRPs-drug-related problems. ''A DRP exists when a patient experiences (or is likely to experience) either a disease or symptom having an actual or suspected relationship with drug therapy'' [7] . Medicine-related problems include issues related to medicine effectiveness, adverse reactions and non-adherence to the treatment.
Non-adherence to the treatment is one of the most common medicine-related problems in patients who suffer from chronic diseases. It has been estimated that the PD patients' adherence to the treatment is only 39%, compromising the benefits of the therapy [6] . Younger patients, patients with complex therapeutic regimens (several pills per day), high depression, and low QoL are less adherent to the antiparkinsonian treatment [8] [9] [10] . Clinical consequences of non-adherence to the antiparkinsonian treatment include loss of motor functions and reduction in QoL [11, 12] . The commitment of health professionals and patients together contributes to improvement of treatment adherence [5, 8, 13] . Furthermore, non-adherence increases PD-related costs because of the increase in hospital admissions, medical appointments and other healthcare services [6] . [16] [17] [18] .
In view of the benefits that MTM represents for PD patients, and given the complexity of the disease and treatment, this study aims to analyze the effects of MTM on the patients' QoL, motor and non-motor symptoms, and medicine-related problems, describing the main pharmaceutical interventions performed.
METHODS

Study Design
A quasi-experimental uncontrolled before-and-after study [19] [20, 21] .
Patients
At the moment of the study, 161 patients diagnosed with Parkinson's disease (International Classification of Disease G20) were registered in the SCPA pharmacy. The patients and/or the caregiver were contacted and invited to participate in this study during the dispensing session of antiparkinsonian medicines by pharmacist AAF during her shift.
After being informed about the MTM process, the participating patients/caregivers signed an Informed Consent Form (ICF) and the first appointment was scheduled. Patients living in nursing homes or patients with discontinued treatment were excluded.
Medication Therapy Management Service
The MTM service was carried out by two pharmacists qualified for clinical pharmaceutical assessment who had knowledge about PD and its treatment.
Additionally, all the parameters included in the assessment were agreed between pharmacist and patient prior to the study in order to standardize the data collection. The provision of the MTM service considered the patient's health needs related to PD and co-morbidities.
The data record forms were designed based on the Pharmacotherapy Workup and the Dader methods [16, [22] [23] [24] After analyzing the aforementioned data, the pharmacist identified potential medicine-related problems reported by the patients in the appointments. The problems were classified according to Cipolle et al. [16] as indication, effectiveness, safety and adherence.
When a medicine-related problem was identified, the pharmacist designed an intervention procedure in order to solve it based on clinical, familiar, and social context data; the latter two were collected using the genogram [28, 29] and ecomap [30] [31] [32] In order to record the follow-up data, the SOAP (Subjective, Objective, Assessment Plan) [33] was used.
Main Outcomes Analyzed
The effects of MTM upon PD patients were assessed considering QoL improvement or maintenance as a primary outcome. 
Data Analysis
The results of the descriptive analysis were expressed as median ± standard deviation, and frequency was expressed in percentage (%). For the analysis, (1) the Student's t test, (2) the Fisher's Chi square test (v 2 ), and (3) the one-way ANOVA test were used respectively for: (1) calculating the association between 2 averages:
inter-and intra-groups; (2) 
RESULTS
Seventy of the 161 PD patients registered in the SCPA were included in the study. The main reason why some patients declined to participate was difficulty to get to the pharmacy. Fifty-one of the 70 participating patients completed the expected 6 months of MTM. Figure 1 shows the sampling flowchart.
Fig. 1 Sampling flowchart
The socio-demographical baseline data of the studied population is shown in Table 1 .
In the first appointment, 35 patients reported rigidity and 35 reported tremors as predominant PD motor symptoms. The most frequent autonomic disorders were constipation (43%), speech disorder (36%), dysphagia (28%), and urinary dysfunction (28%). The most frequent neurological co-morbidities were depression (42.3%), sleep disorder (30.8%), and dementia associated with PD (28%).
Medicine-Related Problems
Types and frequency of the medicine-related problems are shown in Table 2 .
One hundred sixteen medicine-related problems were identified (mean 1. was resolved (Table 3) . 103 (25.5%) of the 404 interventions were aimed to resolve the medicine-related problems. These interventions were more effective to resolve the problems related to non-adherence (n = 43;
46.5%) and adverse reactions (n = 13; 68%). For some of the identified problems, interventions were not carried out by the pharmacist because the patient had had a follow-up visit prior to the appointment with the pharmacist and his/her doctor had changed the treatment. Furthermore, out of the 297 interventions (73.5%) aimed to resolve PD-related problems, 200 (67.3%) were accepted and in 152 of these (76%) the problem was resolved. The most Table 3 Pharmaceutical interventions performed, accepted, and solved by conduct (n = 404) The MTM sessions showed that issues such as self-knowledge, empowerment facing the disease and treatment, stigma, participation in support groups, caregiver/family strengthening, encouragement to non-pharmacological treatments and healthier life were not stimulated by any health professional involved in the patient's care. However, the patients that were part of the APASC support group (15.7% of the patients) were already being helped with these issues.
MTM Outcomes
The outcomes before and after the MTM service are described in Table 4 . It consists of an intention-to-treat (ITT) analysis.
Quality of Life
After the MTM service, all the PDQ-39 scores improved; however, a statistically significant improvement (p = 0.012) was perceived only in the item related to emotional wellbeing (PDQ3).
In spite of the short period of analysis, these data represent a positive clinical impact of MTM upon the PD patients' QoL. The improvement of the PDQ-39 scores before and after MTM was not correlated with adherence, cognition, age, or sex.
Motor and Non-Motor Symptoms
The On/Off state of motor symptoms from the perspective of the patients/caregivers did not vary from the first to the sixth appointments.
The results for the non-motor symptoms showed that in general all the symptoms were to some extent relieved after the MTM service.
Best results were obtained for the control of constipation, dysphagia, gastric dysfunction, and hypotension. 
Medicine-Related Problems Resolution
DISCUSSION
Parkinson's disease is a complex condition due to the progressive nature of its motor and non-motor symptoms, in addition to the fact that PD medicines quickly lose their effectiveness and cause long-term side effects. These characteristics create the necessity of a comprehensive approach towards a constant monitoring of the pharmacological therapy and the PD effects on the patients' QoL [37] . These characteristics consider QoL as a primary outcome in PD [3] . Furthermore, because of the particularities of the disease, individualized interventions are required.
As previously indicated, most of the interventions were performed in a period of up to 2 years and between 5 and 10 years after the diagnosis, as these are the two critical periods in Not assessed: when neither the patient or the caregiver was able to attend the appointment and someone else went to the pharmacy to get the medicines for them the PD patient's life. Up to 2 years, the patient experiences a period of adaptation and acceptance of the diagnosis. In the period from 5 to 10 years, the PD patient faces complications related to the treatment and the disease's progression [38] .
Based on MTM, the analysis detected health problems related and not related to medicines. Our results demonstrate that even though most of the identified health problems were not medicine-related, they could be resolved by pharmaceutical interventions. For instance, autonomic disorders were one of the most frequent problems not related to medicines and can result from the disease's progression and/or antiparkinsonian medication side effects. Their negative effects on the PD patients' QoL were also mentioned in other studies [39] [40] [41] . The symptoms can be relieved by means of nonpharmacological measures or by OTC medicines. Therefore, this type of interventions became important in the pharmaceutical practice.
Although there are few studies about medicine-related problems in PD patients, the results of the present study were similar to those of other published papers. Our results show that the medicine-related problems were more frequently related to non-adherence, adverse reactions, necessity of additional medication and underdose. In another study carried out in community pharmacies, most DRPs concentrated on the need of additional medicines (26.3%) and adverse reactions (12.4%) [14] . In another study at a nursing home, most DRPs concentrated on unnecessary medications (28%) and underdose (14%) [15] .
According to Schröder et al. [14] , underdose may be associated with the prevention of Moreover, our results corroborate those reported by Navarro-Peternella and Marcon [44] ,which demonstrated the necessity of individualized professional interventions based on actions that represent the real needs of the PD patient and/or caregiver. Guidance and information about the disease, its progression, and ways of facing it are fundamental for patient, caregiver, and family. The healthcare services for PD patients must aim to minimize the limitations resulting from the disease's progression and contribute to the improvement or maintenance of their QoL [3] . Regarding the outcomes of the MTM service related to QoL, and despite the short period of analysis, this study produced a positive clinical impact. It is worth remarking that one of the health professional's biggest challenges is to prepare his/her therapeutic plan in a way that the patient's QoL reaches a level that can be considered good [44, 45] .
The improvement of the PDQ-39 score regarding emotional wellbeing after the MTM process confirms the previously reported humanistic positive impacts of MTM on the patient's life [18, 46] . During this process, the patient is seen as an individual with rights, knowledge, and experience and is treated as a partner in the planning of his/her care, being responsible for taking the final decision in the therapeutic conduct [16] . This horizontal relationship between pharmacist and patient generates a transparent environment of trust and credibility necessary for establishing a therapeutic alliance. In addition the perception of the patient as the central figure of the pharmaceutical care within their family and social context, singularity, complexity, and subjectivity contributed to a more comprehensive care. This way of generating healthcare may have contributed to the improvement of the PD patient's wellbeing.
MTM was not able to improve or stabilize the patients' motor symptoms. A contributing factor is the absence of medicines that actually delay the disease's progression, which undoubtedly leads to the worsening of the motor symptoms. Nevertheless, MTM has a considerable impact on the relief of non-motor symptoms, thus contributing to the PD patients' QoL.
Variations in the results of adherence assessed by different methods were also reported by Perseguer-Torregrosa et al. [47] .
This difference reflects the way that each method considers the patient's role during the therapy. While the Morisky questionnaire evaluates adherence as the simple act of taking the medication (compliance), the clinical interview method sees the patient as an active partner in the adherence process and considers the patient's will to collaborate with the treatment (concordance) [48, 49] . In this sense, once the most practical method to evaluate the treatment adherence, especially for elderly patients, is by interviewing the patients or their caregivers [50] , the adherence improvement assessed in our study can be considered a significant result of the MTM service for PD patients.
Limitations
This study was conducted at a public community pharmacy which is the only outpatient setting that dispenses antiparkinsonian medicines in the city, except levodopa which is dispensed at primary healthcare pharmacies. As we used the convenience sampling method including only the patients that we could contact instead of a random sample, a selection bias may have occurred. However, the characteristics of the population under analysis are similar to those reported in other studies [51] [52] [53] [54] [55] .
The sample loss can be considered a limiting factor of the statistical analysis. 
